# A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

> **NCT02415400** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 4614 (actual)

## Conditions studied

- Acute Coronary Syndromes

## Interventions

- **DRUG:** Apixaban
- **DRUG:** vitamin K antagonist
- **DRUG:** Acetylsalicylic acid
- **OTHER:** Acetylsalicylic acid placebo

## Key facts

- **NCT ID:** NCT02415400
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-04
- **Primary completion:** 2018-11-10
- **Final completion:** 2018-11-10
- **Target enrollment:** 4614 (ACTUAL)
- **Last updated:** 2020-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415400, "A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02415400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*